• Niagen Bioscience outlined a strategy centered on NAD+ science, led by its patented nicotinamide riboside supplement franchise.
• Tru Niagen positioned as the No. 1 NAD+ healthy aging supplement in the U.S., supported by clinician sharing on FrontrowMD.
• Niagen Plus targeted a NAD+ IV and injections market estimated at about $500 million, citing improved administration time and fewer side effects.
• Niagen IV reported distribution in more than 1,700 clinics nationwide, including large wellness providers.
• Pipeline expanded beyond supplements into Nanocloud skincare and drug development for rare genetic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.